Bright Minds Biosciences (Bright Minds Biosciences) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bright Minds Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Bright Minds Biosciences's long-term debt to total assets ratio declined from Mar. 2023 (0.00) to Mar. 2024 (0.00). It may suggest that Bright Minds Biosciences is progressively becoming less dependent on debt to grow their business.

Bright Minds Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Bright Minds Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences LT-Debt-to-Total-Asset Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

LT-Debt-to-Total-Asset

0.01

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial													-	-	-	-	-

Bright Minds Biosciences LT-Debt-to-Total-Asset Calculation

Bright Minds Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )	/	Total Assets (A: Sep. 2023 )
	=	0	/	5.084
	=

Bright Minds Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0	/	4.825
	=

Bright Minds Biosciences (NAS:DRUG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bright Minds Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

DRUG:Canada

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.